Safety and Immunogenicity of Trivalent Subunit Influenza Vaccine Produced in Mammalian Cell Culture Using the Strain Composition 2007/2008

NCT ID: NCT00511914

Last Updated: 2013-01-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-07-31
• Study Completion Date: 2007-08-31

Brief Summary

Annual trial for registration of sub-unit influenza vaccine produced in mammalian cell culture, using the strain composition 2007/2008, when administered to adult and elderly subjects

Conditions

Seasonal Influenza Vaccine

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

cTIV (Adults)

Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).

Group Type: EXPERIMENTAL

cTIV

Intervention Type: BIOLOGICAL

One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle

cTIV (Elderly)

Received one dose of cell-culture derived trivalent influenza vaccine (cTIV).

Group Type: EXPERIMENTAL

cTIV

Intervention Type: BIOLOGICAL

One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle

Interventions

cTIV

One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

Subjects eligible for enrollment into this study are male and female adults who were:

1. ≥ 18 years of age, mentally competent, willing and able to give informed consent prior to study entry

2. available for all the visits scheduled in the study and able to comply with all study requirements

3. in good health as determined by:

• medical history
• physical examination
• clinical judgment of the investigator Written informed consent had to be obtained from all the subjects before enrollment in the study after the nature of the study had been explained.

Exclusion Criteria

Subjects were not to be enrolled into the study if at least one of the following criteria was fulfilled:

1. Any serious chronic or acute disease such as:

1. Cancer (leukemia, lymphomas, neoplasm), except for benign or localized skin cancer and non-metastatic prostate cancer not presently treated with chemotherapy

2. Congestive heart failure

3. Advanced arteriosclerotic disease

4. Chronic obstructive pulmonary disease (COPD) requiring oxygen therapy and/or acute exacerbation of a COPD within the last 14 days.

5. Autoimmune disease (including rheumatoid arthritis), if under immunosuppressive therapy (see below)

6. Insulin dependent diabetes mellitus

7. Acute or progressive hepatic disease

8. Acute or progressive renal disease

9. Severe neurological or psychiatric disorder

2. History of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine or chemically related substances

3. Known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting for example from:

1. Receipt of immunosuppressive therapy (chronic therapy with immunosuppressive drugs, any parenteral or oral corticosteroid (substitution dose in case of absence of suprarenal function allowed) or cancer chemotherapy/radiotherapy) within the last 2 months and for the full length of the study,

2. Receipt of immunostimulants,

3. Receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within the past 3 months and for the full length of the study,

4. Suspected or known HIV infection or HIV-related disease.

4. Known or suspected history of drug or alcohol abuse

5. Bleeding diathesis or receive anticoagulants of the coumarin type

6. Women who are pregnant or woman of childbearing potential unwilling to practice acceptable contraception for the duration of the study (21 days)

7. Influenza immunization or laboratory confirmed influenza within the last 6 months and more than one influenza immunization within the past 12 months

8. Immunization with any other vaccine and/or any investigational vaccine four weeks prior to study start

9. Any significant acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the last 7 days

10. Fever (i.e. body temperature ≥ 38.0°C) within the past 3 days prior to study entry

11. Simultaneous participation in another clinical study

12. Any condition, which, in the opinion of the investigator, might prevent the subject from participation or interfere with the evaluation of the study objectives.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Novartis Vaccines

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Vaccines

Role: STUDY_CHAIR

Novartis Vaccines

Locations

Betriebsaerztlicher Dienst, Standort Marburg

Baldingerstrasse, Marburg Hessen, Germany

Z29, Blutspendezentrale, Gebaude Z29, Behringwerke

Emil-von-Behring-Str. 76, Marburg, Germany

Countries

Germany

Other Identifiers

2007-001404-20

Identifier Type: -

Identifier Source: secondary_id

V58P1S

Identifier Type: -

Identifier Source: org_study_id